IN 25. UPREGULATION OF DCX AND DCDC1 IN GLIOBLASTOMA MULTIFORME Wesley J. Whitson, M. Oskar Nowicki, Nina Dmitrieva, Rachel Kantosky, E. Antonio Chiocca and Sean E. Lawler, Dardinger Laboratory for Neurosciences and Neuro Oncology, Division of Neurological Surgical treatment, The Ohio State University Healthcare Center, Columbus, OH, USA The microtubule binding protein doublecortin recommended reading regulates neu ronal migration throughout improvement and has recently been identified as a prospective professional invasive gene in glioblastoma multiforme. On this examine, we established the expression of DCX and also the related molecule doublecortin domain containing protein one in glioma cell lines and patient tumor specimens. We observed 5 to many hundred fold upregula tion of the two genes in glioma cell lines compared with standard astrocytes and in four of 6 and 6 of six GBM samples compared with regular brain tissue.
In these specimens, enhanced expression of up to 100 fold was observed for each genes. Upregulation was confirmed by immunostaining for DCX and Western blotting for DCDC1. In ongoing studies, we’re assessing the functional significance of those genes in glioma biology, par ticularly with regard to cell migration/invasion. Healthcare AND SURGICAL THERAPIES, Grownup TA 01. All round selelck kinase inhibitor SURVIVAL OF Key GLIOBLASTOMA Sufferers Getting RADIATION AND CONCURRENT TEMOZOLOMIDE FOLLOWED BY ROTATIONAL MULTI AGENT CHEMOTHERAPY Mary Lou Affronti, Jeannette M. Dowell, James E. Herndon II, Joan Cahill, Jeremy N. Wealthy, Jennifer A. Quinn, David A. Reardon, James J. Vredenburgh, Annick Desjardins, Sridharan Gururangan, and Henry S. Friedman, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA We conducted a retrospective information analysis to determine the general survival rate of 82 key GBM patients who had been diagnosed at Duke among 2000 and 2004 and who received radiation therapy and concur lease temozolomide, followed by adjuvant rotational multiagent chemo therapy for 12 months.
Our adjuvant method utilized various chemotherapeutic agents with dif ferent tumoricidal

mechanisms to prevent tumor resistance. Twenty seven percent of the sufferers have been women, and 73% were men. The mean age was 52 years, 39% had been 50 years. Eighty two percent of individuals have been white, 4% were African Ameri can, and 14% had been other races. Fifteen percent of individuals had an ECOG performance status score of 0, 61% an ECOG score of one, 20% an ECOG score of 2, and 4% an ECOG score of 3. Total survival was 57% at one year and 31% at 2 years. Median survival was 63. four weeks with a median follow up of 86 weeks. Seventy five percent of patients underwent surgi cal resection, and 25% underwent biopsy alone. A previous meta evaluation of 12 randomized trials comparing additional adjuvant chemotherapy to radiation alone demonstrated only a 5% increase in the 2 year survival rate.